Literature DB >> 15795593

Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms.

Ulrika Lorentzon Fagerberg1, Lars Lööf, Urban Myrdal, Lars-Olof Hansson, Yigael Finkel.   

Abstract

OBJECTIVES: The protein calprotectin is mainly derived from neutrophils. Increased fecal excretion of calprotectin has been reported in inflammatory bowel disease. The recommended cut-off level in adults (<50 microg/g feces) seems to be applicable in children aged 4 to 17 years. The aim of this study was to evaluate the use of fecal calprotectin to detect colorectal inflammation in children with gastrointestinal symptoms.
METHODS: We obtained stool samples on thirty-six children with gastrointestinal symptoms and suspected inflammation of the colon before they underwent colonoscopy. The samples were examined with an improved fecal calprotectin enzyme-linked immunosorbent assay method (Calprest, Eurospital). The results were correlated with the histopathologic findings in the colon.
RESULTS: In children with colorectal inflammation (n = 22) the median fecal calprotectin concentration was 349 microg/g (range, 15.4-1860 microg/g). The most common diagnosis in this group was inflammatory bowel disease. Median fecal calprotectin was 16.5 microg/g (range, 5.0-65 microg/g) in children with no inflammation (n = 14). When <50 microg/g was used as upper reference limit the fecal calprotectin test had a sensitivity of 95%, specificity 93%, positive predictive value 95% and negative predictive value 93% to detect colorectal inflammation.
CONCLUSIONS: The improved fecal calprotectin enzyme-linked immunosorbent assay is a simple test with potential use in children. Increased fecal calprotectin strongly predicted the presence of colorectal inflammation in children with gastrointestinal symptoms. Fecal calprotectin can be used to select patients who should undergo diagnostic colonoscopy for investigation of colorectal inflammation, including inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795593     DOI: 10.1097/01.mpg.0000154657.08994.94

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  32 in total

1.  The rate of bloodstream infection is high in infants with short bowel syndrome: relationship with small bowel bacterial overgrowth, enteral feeding, and inflammatory and immune responses.

Authors:  Conrad R Cole; Juliana C Frem; Brian Schmotzer; Andrew T Gewirtz; Jonathan B Meddings; Benjamin D Gold; Thomas R Ziegler
Journal:  J Pediatr       Date:  2010-02-20       Impact factor: 4.406

Review 2.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

3.  Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Obbe F Norbruis; Johanna C Escher; Angelika Kindermann; Yolanda B de Rijke; Patrick F van Rheenen; Marjolein Y Berger
Journal:  Ann Fam Med       Date:  2016-09       Impact factor: 5.166

Review 4.  [Small intestine, pancreas and islet cell transplantation].

Authors:  C Lackner; F Offner; H Nizze
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

5.  Are child anxiety and somatization associated with pain in pain-related functional gastrointestinal disorders?

Authors:  Amy E Williams; Danita I Czyzewski; Mariella M Self; Robert J Shulman
Journal:  J Health Psychol       Date:  2013-10-22

Review 6.  Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.

Authors:  Ioannis D Kostakis; Kyriaki G Cholidou; Aristeidis G Vaiopoulos; Ioannis S Vlachos; Despina Perrea; George Vaos
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

7.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

8.  Fecal calprotectin excretion in preterm infants during the neonatal period.

Authors:  Carole Rougé; Marie-José Butel; Hugues Piloquet; Laurent Ferraris; Arnaud Legrand; Michel Vodovar; Marcel Voyer; Marie-France de la Cochetière; Dominique Darmaun; Jean-Christophe Rozé
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

Review 9.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

10.  Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.

Authors:  A Damms; S C Bischoff
Journal:  Int J Colorectal Dis       Date:  2008-07-16       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.